These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
646 related articles for article (PubMed ID: 25040297)
1. The role of serum erythropoietin level and JAK2 V617F allele burden in the diagnosis of polycythaemia vera. Ancochea A; Alvarez-Larrán A; Morales-Indiano C; García-Pallarols F; Martínez-Avilés L; Angona A; Senín A; Bellosillo B; Besses C Br J Haematol; 2014 Nov; 167(3):411-7. PubMed ID: 25040297 [TBL] [Abstract][Full Text] [Related]
2. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF). Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic Performance of Erythropoietin Levels in Polycythemia Vera: Experience at a Comprehensive Cancer Center. Davila-Gonzalez D; Barrios-Ruiz A; Fountain E; Cheng L; Masarova L; Verstovsek S; Rojas-Hernandez CM Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):224-229. PubMed ID: 33349602 [TBL] [Abstract][Full Text] [Related]
4. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea. Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451 [TBL] [Abstract][Full Text] [Related]
5. Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients. Besses C; Alvarez-Larrán A; Martínez-Avilés L; Mojal S; Longarón R; Salar A; Florensa L; Serrano S; Bellosillo B Br J Haematol; 2011 Feb; 152(4):413-9. PubMed ID: 21219298 [TBL] [Abstract][Full Text] [Related]
6. Elevated serum erythropoietin levels in patients with Budd-Chiari syndrome secondary to polycythemia vera: clinical implications for the role of JAK2 mutation analysis. Thurmes PJ; Steensma DP Eur J Haematol; 2006 Jul; 77(1):57-60. PubMed ID: 16827884 [TBL] [Abstract][Full Text] [Related]
7. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644 [TBL] [Abstract][Full Text] [Related]
9. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600 [TBL] [Abstract][Full Text] [Related]
10. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders. Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609 [TBL] [Abstract][Full Text] [Related]
11. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera. Ganly P; Hanrahan V; Baker B; Romeril K Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638 [TBL] [Abstract][Full Text] [Related]
12. Comparison of JAK2V617F mutation assessment employing different molecular diagnostic techniques. Veneri D; Capuzzo E; de Matteis G; Franchini M; Baritono E; Benati M; Solero GP; Ambrosetti A; Quaresmini G; Pizzolo G Blood Transfus; 2009 Jul; 7(3):204-9. PubMed ID: 19657484 [TBL] [Abstract][Full Text] [Related]
13. Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation. Hexner E; Roboz G; Hoffman R; Luger S; Mascarenhas J; Carroll M; Clementi R; Bensen-Kennedy D; Moliterno A Br J Haematol; 2014 Jan; 164(1):83-93. PubMed ID: 24903629 [TBL] [Abstract][Full Text] [Related]
14. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype. Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178 [TBL] [Abstract][Full Text] [Related]
15. Polycythemia vera is not initiated by JAK2V617F mutation. Nussenzveig RH; Swierczek SI; Jelinek J; Gaikwad A; Liu E; Verstovsek S; Prchal JF; Prchal JT Exp Hematol; 2007 Jan; 35(1):32-8. PubMed ID: 17198871 [TBL] [Abstract][Full Text] [Related]
16. A refined diagnostic algorithm for polycythemia vera that incorporates mutation screening for JAK2(V617F). Tefferi A Curr Hematol Malig Rep; 2006 Jun; 1(2):81-6. PubMed ID: 20425336 [TBL] [Abstract][Full Text] [Related]
17. High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden. Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC Hematology; 2008 Apr; 13(2):71-6. PubMed ID: 18616871 [TBL] [Abstract][Full Text] [Related]
18. Proteomic study of the impact of the JAK2-V617F mutation on the phenotype of essential thrombocythemia. Mossuz P; Arlotto M; Hermouet S; Bouamrani A; Lippert E; Girodon F; Dobo I; Vincent P; Cahn JY; Berger F Exp Hematol; 2008 Dec; 36(12):1642-7. PubMed ID: 18838204 [TBL] [Abstract][Full Text] [Related]